Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers

Journal of Alternative and Complementary Medicine

Volumn 11, Issue 6, 2005, Pages 1031-1038

  Li, Zhaoping ^a   Seeram, Navindra P ^a   Lee, Rupo ^a   Thames, Gail ^a   Minutti, Chayo ^a   Wang, He Jing ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PIGMENT; PLANT MEDICINAL PRODUCT; TANNIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE MEDICINE; CHINESE RED YEAST RICE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MASS SPECTROMETRY; MONASCUS; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RICE;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL PRODUCTS; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; PLASMA; REFERENCE VALUES;

EID: 31144436097     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2005.11.1031     Document Type: Article

References (25)

1. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-211.
2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998;280:1569-1575.
3. Wootton JC, Sparber A. Surveys of complementary and alternative medicine: Part 1. General trends and demographic groups. J Altern Complement Med 2001;7:195-208.
4. Havel RJ. Dietary supplement or drug? The case of cholestin. Am J Clin Nutr 1999;69:175-176.
5. Stuart MD. Chinese materia medica: Vegetable kingdom. Taipai, Republic of China: Southern Materials Center, 1979.
6. Martinkova L, Patakova-Juzlova P, Krent V, et al. Biological activities of oligoketide pigments of Monascus purpureus. Food Addit Contam 1999;16:15-24.
7. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-236.
8. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402.
9. Wu Y, Zhao J, Henion J, Korfmacher WA, Lapiguera AP, Lin CC. Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry. J Mass Spectrom 1997;32:379-387.
10. Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5225.
11. Endo A, Monacolin K: A new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32:852-854.
12. Wu LC, Chen YC, Ho JA, Yang CS. Inhibitory effect of red koji extracts on mushroom tyrosinase. J Agric Food Chem 2003;51:4240-4246.
13. Wei W, Li C, Wang Y. Su H, Zhu J, Kritchevsky D. Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpurens-fermented rice, red yeast rice) in cholesterol fed rabbits. J Nutr Biochem 2003;14:314-318.
14. Li C, Zhu Y, Wang Y, Zhu J-S, Chang J, Kritchevsky D. Monascus purpureus-fermented rice (red yeast rice): A natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutrition Res 1998;18:71-81.
15. Edwards PA, Popjak G, Fogelman AM, Edmond J. Control of 3-hydroxy-3-methylglutaryl coenzyme A reductase by endogenously synthesized sterols in vitro and in vivo. J Biol Chem 1977;252:1057-1063.
16. Duggan DE, Chen IW, Bayne WF, et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989;17:166-173.
17. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: Implications of variability in chemical profile and contents. J Altern Complement Med 2001;7:133-139.
18. Erturk S, Onal A, Muge CS. Analytical methods for the quantitative determination of 3-hydroxy-3-mcthylglutaryl coenzyme A reductase inhibitors in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;793:193-205.
19. Lamson M, Phillips G, Shen J, Lukacsko P, Friedhoff L, Niecestro RM. Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 2002;23:143-149.
20. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
24. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732.
25. Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:11150-11157.